Intra-Cellular Therapies Soars 32% With Johnson & Johnson's $14.6B Acquisition
J&J's acquisition of Intra-Cellular Therapies reshapes its portfolio with schizophrenia, bipolar, and Alzheimer's treatments.
Johnson & Johnson to Acquire Intra-Cellular in $14.6B Deal
Johnson & Johnson agreed to acquire Intra-Cellular Therapies for $132 a share in cash for a total equity value of about $14.6 billion. The health-care company Monday said the deal adds to its ...
The Motley Fool9d
Johnson & Johnson (NYSE: JNJ)
Johnson & Johnson is a holding company ... Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets. The Pharmaceutical segment focuses on therapeutic areas ...
Hold Rating for Johnson & Johnson Amid Modest Growth Outlook and Legal Uncertainties
In a report released today, Tim Anderson from Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research ...
Johnson & Johnson (JNJ) Gets a Hold from Barclays
Barclays analyst Matt Miksic maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) today and set a price target of $160.00.
Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression ...
Pharm Exec7d
Johnson & Johnson Acquires Intra-Cellular Therapies to Bolster Mental Health Business
According to the company, the acquisition includes Caplyta (lumateperone), a once-daily oral ... care and advancing research in some of today’s most devastating neuropsychiatric and neurodegenerative ...